Results 81 to 90 of about 492,703 (122)

Identification, Synthesis, and Strategy For Minimization of Potential Impurities Observed In Raltegravir Potassium Drug Substance

Organic Process Research & Development, 2012
Multiple sources of anticipated degradation and process impurities of raltegravir potassium drug substance observed during the laboratory optimization and later during its bulk synthesis are described in this article. The impurities were monitored by UPLC, and their structures are tentatively assigned on the basis of fragmentation patterns in LC–MS and
Gulabrao D. Patil, Siddheshwar W. Kshirsagar, Shivnath B. Shinde, Pankaj S. Patil, Mangesh S. Deshpande, Ashok T. Chaudhari, Swapnil P. Sonawane, Golak C. Maikap, Mukund K. Gurjar   +8 more
semanticscholar   +3 more sources

Crystal structure of raltegravir potassium, C₂₀H₂₀FKN₆O₅

Powder Diffraction, 2015
The crystal structure of the potassium salt of raltegravir has been solved and refined using synchrotron X-ray powder diffraction data, and optimized using density functional techniques. Raltegravir potassium crystallizes in space groupP21/c(#14) witha= 15.610 59(9),b= 8.148 19(3),c= 16.125 97(6) Å,β= 94.1848(5)°,V= 2045.72(1) Å3, andZ= 4.
James A. Kaduk, Kai Zhong, Amy M. Gindhart, Thomas N. Blanton   +3 more
semanticscholar   +3 more sources

Biowaiver monograph for immediate-release solid oral dosage forms: Raltegravir potassium

Journal of Pharmaceutical Sciences
The present monograph discusses the possibility of BCS-based biowaivers for immediate release pharmaceutical products containing raltegravir potassium, which is used to treat human immunodeficiency virus (HIV) infections. Raltegravir potassium can be assigned to BCS class II or IV since this compound has low solubility and uncertain permeability ...
Atsushi Kambayashi, Masaki Iida, Makoto Ishihara, Yoshinori Takahashi, Bertil Abrahamsson, Naseem A. Charoo, Rodrigo Cristofoletti, Peter Langguth, Mehul Mehta, Alan Parr, James E. Polli, Vinod P. Shah, Jennifer Dressman   +12 more
semanticscholar   +4 more sources

Development of a Second-Generation, Highly Efficient Manufacturing Route for the HIV Integrase Inhibitor Raltegravir Potassium

Organic Process Research & Development, 2010
A manufacturing route for the synthesis of raltegravir potassium 1 was developed via a thermal rearrangement of amidoxime DMAD adducts 6 to construct the key, highly functionalized hydroxypyrimidin...
Guy R. Humphrey, Philip J. Pye, Yong-Li Zhong, Remy Angelaud, David Askin, Kevin M. Belyk, Peter E. Maligres, Danny E. Mancheno, Ross A. Miller, Robert A. Reamer, Steven A. Weissman   +10 more
semanticscholar   +3 more sources

DoE-Based Solid Self-microemulsifying Drug Delivery System (S-SMEDDS) Approach for Improving the Dissolution Properties of Raltegravir Potassium

Journal of Pharmaceutical Innovation, 2022
Sourabhkumar Jain, Kiran Dudhat, M. M. Soniwala, Nirav Kotadiya, Dhavalkumar Mori   +4 more
semanticscholar   +3 more sources

A Polar Radical Pair Pathway To Assemble the Pyrimidinone Core of the HIV Integrase Inhibitor Raltegravir Potassium

Angewandte Chemie, 2008
Philip J, Pye, Yong-Li, Zhong, Gavin O, Jones, Robert A, Reamer, Kendall N, Houk, David, Askin   +5 more
semanticscholar   +5 more sources

An Insight into Interactional Characteristics of Aqueous Raltegravir Potassium in Potassium Chloride and α-Lactose via Volumetric, Compressibility, and Viscometric Properties

Journal of Solution Chemistry
Rojo John, Vijay M. Tangde, Niraj T. Khaty, Prafulla M. Sable   +3 more
semanticscholar   +3 more sources

Synthesis of the HIV Integrase Inhibitor Raltegravir Potassium

Synfacts, 2011
Contributor Philip Kocienski, P. J. Pye, Y.-L. Zhong et al.   +2 more
semanticscholar   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

The integrase inhibitors dolutegravir and raltegravir exert pro-adipogenic and profibrotic effects and induce insulin resistance in human/simian adipose tissue and human adipocytes.

Clinical Infectious Diseases, 2020
BACKGROUND Although some integrase strand transfer inhibitors (INSTIs) promote peripheral and central adipose tissue/weight gain in HIV-infected individuals, the underlying mechanism has not been identified.
Jennifer Gorwood, C. Bourgeois, V. Pourcher, G. Pourcher, F. Charlotte, M. Mantecon, C. Rose, R. Morichon, M. Atlan, R. Le Grand, D. Desjardins, C. Katlama, B. Fève, O. Lambotte, J. Capeau, V. Béréziat, C. Lagathu   +16 more
semanticscholar   +3 more sources

Raltegravir Potassium

, 2021
openaire   +2 more sources